Cholesterol-induced colorectal cancer progression and its mitigation through gut microbiota remodeling and simvastatin treatment - BMC Cancer Background Elevated serum cholesterol levels are linked to an increased risk of colorectal adenomas and colorectal cancer (CRC), yet the role of serum low-density lipoprotein (LDL) in CRC development remains unclear. This study explores the impact of cholesterol on tumor growth and the potential therapeutic effects of Lactobacillus and Simvastatin. Methods We utilized a cecal tumor xenograft mouse model with Ldlr−/− mice to assess the effects of high cholesterol levels on tumor growth. Additionally, the role of gut microbiota remodeling and cholesterol-lowering strategies was investigated using Lactobacillus supplementation and Simvastatin treatment. Results Ldlr−/− mice on a high-cholesterol diet developed significantly larger tumors (P < 0.05) and exhibited exacerbated malignancy, as indicated by HE and Ki-67 staining. Lactobacillus supplementation reduced tumor growth (P < 0.05), lowered serum cholesterol levels, and altered the gut microbiota composition, increasing the relative abundance of beneficial bacterial taxa. Simvastatin treatment reduced PD-L1 expression in CRC cells by lowering cholesterol levels, which was associated with decreased CRC proliferation, reduced serum LDL levels, and enhanced T cell infiltration in the tumor microenvironment. Conclusion Elevated serum cholesterol promotes CRC progression, while gut microbiota remodeling through Lactobacillus supplementation and cholesterol-lowering interventions, such as Simvastatin, show potential in mitigating tumor growth and enhancing antitumor immune responses. These findings highlight the importance of cholesterol management in CRC treatment strategies.

Elevated serum cholesterol promotes colorectal cancer progression, while gut microbiota remodeling through Lactobacillus supplementation and cholesterol-lowering interventions show potential in mitigating tumor growth, finds a study in BMC Cancer.
bit.ly/3ZJXzGw

#OncoSky #MedSky

Identification of metabolic biomarkers and therapeutic targets in the thymoma-associated myasthenia gravis treated with methylprednisolone - Discover Oncology Objective This study aims to screen and identify metabolic biomarkers and targets for methylprednisolone treatment of thymoma with myasthenia gravis (MG) through metabolomics and network pharmacology analysis, thereby improving guidance for clinical medication and treatment. Methods Serum from 15 patients with thymoma accompanied by severe MG was collected. Changes in serum metabolite levels before and after methylprednisolone treatment were determined using liquid chromatography-mass spectrometry (LC—MS). The raw mass spectrometry fragment information obtained was integrated and interpreted using the metabolomics data analysis software Progenesis QI v2.3. Differential metabolites were screened and identified using univariate and multivariate statistical analysis methods. Subsequently, potential targets of methylprednisolone treatment were identified through network pharmacology, and the mechanism of action of methylprednisolone in treating thymoma with MG was explored in conjunction with metabolomics. Finally, key targets and the upstream synthetic enzymes of critical metabolites identified were validated using Enzyme-Linked Immunosorbent Assay (ELISA). Results A total of 148 differential metabolites were identified in the metabolomics study, among which key metabolites ceramide (Cer) and sphingomyelin (SM) play a significant role in cell immune regulation, inflammatory response, and tumor control. Network pharmacology analysis revealed that tumor necrosis factor (TNF) could serve as a potential target for methylprednisolone treatment of thymoma with MG. ELISA validation results showed that the key target TNF and the upstream synthetic enzymes of the key metabolites SM and Cer were all downregulated after methylprednisolone treatment, with the differences being statistically significant (P < 0.05). Conclusion Our Study reveals that TNF could serve as a potential target for methylprednisolone treatment of Thymoma-associated MG, and Cer and SM could act as potential metabolic biomarkers to assess its treatment efficacy.

A study published in Discover Oncology aims to screen and identify metabolic biomarkers and targets for methylprednisolone treatment of thymoma with myasthenia gravis (MG) through metabolomics and network pharmacology analysis.

#OncoSky #MedSky

Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial Data on bleeding risk from combining prophylactic anticoagulation with drugs that have antiplatelet properties (antiplatelet agents or nonsteroidal an…

#Medsky🧪 #oncosky #publichealth Concurrent use of antiplatelet drugs during apixaban thromboprophylaxis in cancer patients increases clinically relevant bleeding without reducing VTE.
@thjournal.bsky.social
www.sciencedirect.com/science/arti...

A cancer patient enrolled in this trial died because of duloxetine. Adding insult to injury it was already known that duloxetine doesn't work (and why should it?) in the prevention or treatment of chemotherapy induced neuropathy spcare.bmj.com/content/13/1... #MedSky #Oncosky #Pharmsky

For all my fellow NET cancer patients, keep the faith. They are doing research, with some promising results. #Cansky #Oncosky

Building a ready-made cancer data library – Sciworthy Researchers built a cancer database combining 4 types of molecular data across 32 cancer types to enable consistent use of machine learning in cancer research.

Scientists in Japan and the USA created a database, called MLOmics, that compiles genetic and molecular data from more than 8,000 cancer patients and is specifically designed for machine learning applications.
#SciComm #SciNews #CanSky #OncoSky
sciworthy.com/building-a-r...

An Update on Drugs for KRAS Mutations Drugs for KRAS are the focus of a number of clinical trials, and Dr. Allyson Ocean comments on the status of this research.

Drugs for KRAS are the focus of a number of clinical trials, and Dr. Allyson Ocean comments on the status of this research. https://bit.ly/4c1c3c7 #OncoSky #KRAS

New £1m clinical trial launches to improve quality of life for people with blood cancer Researchers have been awarded £1m to launch a new clinical trial for people with myelodysplastic syndromes, a form of blood cancer with limited treatment options.

Congratulations to Dr @kevinrouault.bsky.social, who has been awarded £1m from @cancerresearchuk.org to launch a clinical trial aiming to improve quality of life for people with myelodysplastic syndromes, a form of blood cancer with limited treatment options.

🧪 #medsky #oncosky @qmul.bsky.social

BMC Cancer

A study published in BMC Cancer introduces the Mainz Resilience Assessment in Childhood Cancer (MRAcc), a novel tool to track resilience over time in young cancer patients by capturing mental health and treatment‑specific stressors.
bit.ly/4dyjdoW

#MedSky #Oncosky

Seven Tips to Navigate the Caregiver Learning Curve Brooke Dwars learned quickly to manage her husband's care. Nurse navigator Patricia Gambino and social worker Lauren Shaffer provide other tips for a caregiver.

Brooke Dwars learned quickly to manage her husband’s care. Nurse navigator Patricia Gambino and social worker Lauren Shaffer provide other tips for a caregiver. https://bit.ly/4c9PWOT #OncoSky #CanSky

PRESS RELEASE Fennec Pharmaceuticals Announces Investigator-Sponsored Study to be Conducted by University of Arizona Cancer Center

Today we announced the initiation of an IST by University of Arizona Cancer Center to evaluate use of PEDMARK® (sodium thiosulfate injection). Learn more: bit.ly/4mdtNEh

#ClinicalResearch #ComprehensiveCancerCare #OncoSky

#CanSky #OncoSky

Identification of metabolic biomarkers and therapeutic targets in the thymoma-associated myasthenia gravis treated with methylprednisolone - Discover Oncology Objective This study aims to screen and identify metabolic biomarkers and targets for methylprednisolone treatment of thymoma with myasthenia gravis (MG) through metabolomics and network pharmacology analysis, thereby improving guidance for clinical medication and treatment. Methods Serum from 15 patients with thymoma accompanied by severe MG was collected. Changes in serum metabolite levels before and after methylprednisolone treatment were determined using liquid chromatography-mass spectrometry (LC—MS). The raw mass spectrometry fragment information obtained was integrated and interpreted using the metabolomics data analysis software Progenesis QI v2.3. Differential metabolites were screened and identified using univariate and multivariate statistical analysis methods. Subsequently, potential targets of methylprednisolone treatment were identified through network pharmacology, and the mechanism of action of methylprednisolone in treating thymoma with MG was explored in conjunction with metabolomics. Finally, key targets and the upstream synthetic enzymes of critical metabolites identified were validated using Enzyme-Linked Immunosorbent Assay (ELISA). Results A total of 148 differential metabolites were identified in the metabolomics study, among which key metabolites ceramide (Cer) and sphingomyelin (SM) play a significant role in cell immune regulation, inflammatory response, and tumor control. Network pharmacology analysis revealed that tumor necrosis factor (TNF) could serve as a potential target for methylprednisolone treatment of thymoma with MG. ELISA validation results showed that the key target TNF and the upstream synthetic enzymes of the key metabolites SM and Cer were all downregulated after methylprednisolone treatment, with the differences being statistically significant (P < 0.05). Conclusion Our Study reveals that TNF could serve as a potential target for methylprednisolone treatment of Thymoma-associated MG, and Cer and SM could act as potential metabolic biomarkers to assess its treatment efficacy.

A study published in Discover Oncology aims to screen and identify metabolic biomarkers and targets for methylprednisolone treatment of thymoma with myasthenia gravis (MG) through metabolomics and network pharmacology analysis.

#OncoSky #MedSky

Awareness matters – but so does what comes after.

For many testicular cancer patients, #survivorship should include:
✔️Emotional support
✔️Fertility planning
✔️Hearing health monitoring

Let’s keep the conversation going. What does survivorship mean to you? #testicularcancer

#CanSky #OncoSky

Discover Oncology

A Review published in Discover Oncology examines glycosphingolipids expression in bladder cancer and explores their contributions to key cancer hallmarks, including invasion and metastasis, immune evasion, and resistance to cell death.
bit.ly/4jFyvIU

#MedSky #OncoSky

Analysis of microarray and single-cell RNA-seq identifies gene co-expression, cell–cell communication, and tumor environment associated with metabolite interconversion enzyme in prostate cancer Cancer does not have a universally agreed-upon description, but it is characterized by the unregulated proliferation of cells, which may result in the infiltration of the cell basement or the spread to other organs in the body.

In a Discover Oncology Behind The Paper blog post, the author discusses new perspectives on the molecular properties and pathways of differentially expressed genes in prostate cancer and potential biomarkers that play a crucial role in its genesis.

#MedSky #OncoSky #CanSky

It's been an exciting week around here - let's end it on a high note with this week's #ACSFriday5!

Here are five new papers from our ACS researchers that we think are worthy of a little extra attention this week:

#CanSky #OncoSky 🧪

#Medsky🧪 #IDsky #oncosky #immunosky #publichealth #vaccinesarematter @jama.com In a cohort of 76 807 patients with cancer, no significant elevation in overall risk of postacute sequelae compatible with long COVID was observed among those infected with the #SARSCoV’2

Held at @jax.org in Bar Harbor, you will:
🔹 Engage with experts
🔹 Develop skills in xenografting and data analysis
🔹 Network with peers and faculty
🔹 Present your research

📆 Submit an abstract by July 1: www.jax.org/education-an...

#Oncosky #Cansky #PhDSky

Exploring Cancer: Biology and Inheritance Discover the fundamental properties of cancer cells and explore the genetic basis, inheritance, risk factors and prevention of this disease.

📊 Are you familiar with the six hallmarks of #cancer?

Learn about the fundamental properties of cancer cells and what drives their development in @jax.org's self-paced Online MiniCourse.

#CanSky #OncoSky

Anti-Inflammatory Diet Index (AIDI) and Bladder Cancer Risk by Stage: A 22-Year Prospective Swedish Cohort Study (1998–2020) Abstract. Background: Dietary patterns influencing systemic levels of inflammation have been proposed and investigated as possible determinants of cancer risk. We evaluated the association between the...

New in @theaacr.bsky.social: "In this large cohort with 22 years of follow-up, higher Anti-Inflammatory Diet Index scores were associated with lower bladder cancer risk, especially for muscle-invasive disease."🍒 #bladdercancer #oncology #cansky #oncsky #oncosky
aacrjournals.org/cebp/article...

What passes for healthcare since Trump & RFK Jr took over. #oncosky #healthcare
www.instagram.com/reel/DWb57T9...

📢 We are #hiring!

▫️Group Leader in Chemical Biology
▫️Group Leader in Structural Biology
▫️Purchasing Technician (temporary position)
▫️People Administration Officer

...and more!

 ➡️ https://bit.ly/irbjobs

#IRBJobs #ScienceJobs #JobOffer #OncoSky #AcademicSky

#Medsky🧪 #oncosky Experimental findings from cell lines, 🐁 models, and clinical samples strongly support the role of #tetraploidy in cancer evolution but many studies have reported very large & presumably highly #polyploid cells in drug-resistant & metastatic tumors

Welcome to this week's #ACSFriday5, where we shine the spotlight on new publications from our ACS researchers!

Here are five papers that we think are worth your time this week:

#CanSky #OncoSky 🧪

Waited 65 minutes for my neurosurgeon to join my Zoom appointment at 9:30am. Called the hospital but hung up after hearing, "You are the 8th caller in line". 90 minutes late now...I am thoroughly annoyed. Furious, in fact. 😡 #FuckDougFord #CanSky #OncoSky

🔬 Watch how cancer and immune cells interact in a living system.

Scientists at BCI have developed mini lab-grown ovarian tumours that recreate the complex neighbourhood of cells in patients. Published today in @natcomms.nature.com.

Read more: bit.ly/4bMCrVg

🧪 #medsky #oncosky @qmul.bsky.social

Serum neopterin and kynurenine as predictive and prognostic biomarkers in prostate cancer: the role of dietary inflammatory index and biomarker interactions - BMC Cancer Background It has been shown that neopterin levels in various body fluids can help predict the diagnosis of different malignancies. Although many studies have investigated the roles of serum neopterin concentrations, tryptophan metabolism, and the dietary inflammation index (DII) in various cancers, the connection between these factors and prostate cancer (PC) remains uncertain. The aim of this study was to investigate the predictive and prognostic roles of serum neopterin, and kynurenine levels, along with the kynurenine-to-tryptophan ratio (KTR) and DII in prostate cancer. Methods This study was conducted with 57 newly diagnosed prostate cancer patients, 55 benign prostate hyperplasia patients, and 56 healthy male individuals in the control group, all aged 40 years and older. Participants had specific anthropometric measurements taken, and three-day food records were kept. DII was calculated based on data for thirty-four available nutrients by using food records. Serum levels of neopterin, kynurenine, tryptophan, tumor necrosis factor alpha (TNF-α), and interferon-gamma (IFN-γ) were measured using an enzyme-linked immunosorbent assay (ELISA) method. Results Serum neopterin (11.79 ± 6.09), kynurenine (1655.48 ± 1122.04), TNF-α (221.59 ± 232.06) and IFN-γ (137.68 ± 107.11) levels were higher in the malignant group than in both the control (2.72 ± 0.76, 352.40 ± 69.33, 223.94 ± 226.67, and 23.03 ± 7.28, respectively) and benign groups (3.17 ± 0.74, 377.94 ± 109.05, 179.61 ± 224.36, and 25.63 ± 7.50, respectively) (p < 0.05). Another result of our study is that in the malignant group, serum neopterin levels exhibited significant positive correlations with serum kynurenine (r = 0.80, p < 0.0001), IFN-γ (r = 0.86, p < 0.0001) and TNF-α levels (r = -0.27, p = 0.0453) and DII (r = 0.30, p = 0.0229), while they exhibited weak correlations with serum PSA, and other diet parameters. Additionally, kynurenine was the only parameter showing significant differences in mean values concerning surgical margins (p < 0.05). Conclusions The findings of this study support the hypothesis that serum neopterin and specific tryptophan catabolites (e.g., kynurenine), could serve as predictive and prognostic biomarkers for prostate cancer diagnosis. However, our results do not support the hypothesis that DII and certain dietary factors play a direct role in the development or diagnosis of prostate cancer.

A study published in BMC Cancer supports the hypothesis that serum neopterin and specific tryptophan catabolites (e.g., kynurenine), could serve as predictive and prognostic biomarkers for prostate cancer diagnosis.

#MedSky #OncoSky

Identification of metabolic biomarkers and therapeutic targets in the thymoma-associated myasthenia gravis treated with methylprednisolone - Discover Oncology Objective This study aims to screen and identify metabolic biomarkers and targets for methylprednisolone treatment of thymoma with myasthenia gravis (MG) through metabolomics and network pharmacology analysis, thereby improving guidance for clinical medication and treatment. Methods Serum from 15 patients with thymoma accompanied by severe MG was collected. Changes in serum metabolite levels before and after methylprednisolone treatment were determined using liquid chromatography-mass spectrometry (LC—MS). The raw mass spectrometry fragment information obtained was integrated and interpreted using the metabolomics data analysis software Progenesis QI v2.3. Differential metabolites were screened and identified using univariate and multivariate statistical analysis methods. Subsequently, potential targets of methylprednisolone treatment were identified through network pharmacology, and the mechanism of action of methylprednisolone in treating thymoma with MG was explored in conjunction with metabolomics. Finally, key targets and the upstream synthetic enzymes of critical metabolites identified were validated using Enzyme-Linked Immunosorbent Assay (ELISA). Results A total of 148 differential metabolites were identified in the metabolomics study, among which key metabolites ceramide (Cer) and sphingomyelin (SM) play a significant role in cell immune regulation, inflammatory response, and tumor control. Network pharmacology analysis revealed that tumor necrosis factor (TNF) could serve as a potential target for methylprednisolone treatment of thymoma with MG. ELISA validation results showed that the key target TNF and the upstream synthetic enzymes of the key metabolites SM and Cer were all downregulated after methylprednisolone treatment, with the differences being statistically significant (P < 0.05). Conclusion Our Study reveals that TNF could serve as a potential target for methylprednisolone treatment of Thymoma-associated MG, and Cer and SM could act as potential metabolic biomarkers to assess its treatment efficacy.

A study published in Discover Oncology aims to screen and identify metabolic biomarkers and targets for methylprednisolone treatment of thymoma with myasthenia gravis (MG) through metabolomics and network pharmacology analysis.

#OncoSky #MedSky

My last quarterly CTscan showed no sign of recurrence, BUT showed a nodule on my thyroid gland. An ultrasound showed it has an ACR TI-RADS score of TR4 - a “moderately suspicious nodule.” 🕵🏻‍♂️ 👀

FNA biopsy scheduled. Meanwhile, let’s party! 💃🏼🕺🏻

#FkCancer #CanSky #OncoSky